



# Malaria Programme Implementation status and Gap analysis

**Dr. Jimmy OPIGO, ACHS/Program Manager  
National Malaria Control Division Uganda  
3<sup>rd</sup> October, 2023**

# UMRESP GOAL AND STRATEGIC OBJECTIVES 2020 - 2025

## Vision

A malaria free Uganda to enable socioeconomic transformation in line with vision 2040

**Goal 1: By 2025, reduce malaria infection and morbidity by 50% and malaria related mortality by 75% of 2019 levels**

## SIX STRATEGIC OBJECTIVES

SO 1: Preventive and curative services

SO 2: Quality of malaria care in the private sector

SO 3: Social Behaviour Change

SO 4: Data use for decision making

SO 5: Malaria elimination system in targeted districts

SO 6: Enabling environment to deliver malaria interventions



# Target achievement

	Baseline			2020/2021		2021/2022		2022/2023	
<b>Goal: To reduce malaria infection and morbidity by 50% and malaria-related mortality by 75% of 2019 levels by 2025</b>									
	Year	Value	Source	Target	Result	Target	Result	Target	Result
In-patient malaria deaths (per 100,000 persons per year)	2019	8.9	HMIS	7.7	7.3	6.3	6.8	5.0	6.5
Proportion of malaria deaths of total deaths	2019	10	HMIS	8.5	5.7	7.0	5.0	5.5	6.4
Confirmed malaria cases (per 1000 persons per year)	2019	308	HMIS	277	359	246	374	216	375
Proportion of OPD visits attributed to Malaria	2019	31	HMIS	27.9	30.1	24.8	32.3	21.7	33.9
Test Positivity rate	2019	49.1	HMIS	44.2	44.2	39.3	46.8	34.4	53.1

# Achievements - I

Intervention	Target Population	Coverage
Mass net distribution	Entire population	2020/21 (28.5 million nets, 98.6%) 2023 (Target 28 m, distributed 11.7 across 62 districts so far)
Routine nets	Expanded to include schools in high burden districts in 2022	11 districts 899 schools
Indoor Residual Spraying	Expanded to 9 Districts in West Nile Transitioned 4 districts in Lango to S/C level spraying  Conducted through the Local Government System	In 2020, 16 districts, 11.9% of the population In 2021, 14 districts, 10.4 % of the population 2022, 23 districts, 15.2% of the population

# Achievements - 2

Intervention	Target Population	Coverage
Seasonal Malaria Chemoprevention	Karamoja region	Phase 1 2021, 3 districts (2 intervention, 1 control) reached 80,000 children, 90% Coverage Children in intervention districts had a 92.2% lower risk of developing confirmed malaria in the five-month period of follow-up versus those in the control 2022, additional 6 districts, 140,000 children. 2022, all 9 districts
Integrated Community case Management	Across all 137 districts	Full ICCM package has been scaled up from 33 to in 67 districts (49%) High burden, Hard to reach, and IRS exit districts were prioritized to receive ICCM.

# Bottle necks/Challenges - I

	Challenge	Remedial action
1	<p>Programmatic challenges:</p> <ul style="list-style-type: none"><li>Limited scope &amp; scale of some interventions, delayed implementation, interruption due to exit of donors, synchronization, sustainability of gains, verticalization &amp; limited decentralization.</li></ul>	<p>Transition of IRS to GF Deployment through Local Government structures Sub county level deployment</p>
2	<p>Population/community challenges</p> <ul style="list-style-type: none"><li>Delayed care seeking, Low risk perception of malaria, Incomplete dose taking/sharing of medicines, Ignoring referral advice for advanced care, poor/non use of VC tools</li></ul>	<p>Continuous SBC by leveraging community structures, Provider SBC</p>
3	<p>Increase in malaria cases across the country with epidemics.</p>	<p>Malaria Epidemic Response through IMS with support from MOH Senior Leadership</p>

## Bottle necks/Challenges - 2

	Challenge	Remedial action
4	LLINs, have good overall coverage ~90%, however effect is short lived <1 year, Inconsistent and none use, Attrition, poor physical durability, decreased bio efficacy among others are possible reasons for this	<b>Current campaign has a focus on use, care, and repair of nets</b>
5	ICCM in <50% (63) of districts. Challenged by vertical & projectized implementation modality affecting scope, stocks, referrals & reporting	
6	Biological threats: Drug resistance markers identified in the country, Insecticide resistance – Insecticides in our LLINs, Gene deletions in HRP2/3 genes – affecting RDTs, Changes in vector species and feeding behavior	<b>Intensified surveillance</b>
7	Limited effectiveness of IRS following the deployment of Clothianidin	<b>Entomology Surveillance Switch to Actellic 300 CS</b>
8	Increased Incidence of Malaria Upsurges	Adopted the IMS to monitoring and response

# Best Practices - I

- Continuity of Essential Services during COVID -19
  - Established a coordination forum for malaria partners but also at MOH for all departments and partners
  - Identified challenges to implementation and devised solutions to allow for continuity
  - LLIN campaign, IRS, ICCM all continued during C-19
- Seasonal Malaria Chemoprevention in Karamoja region was successfully delivered according to schedule and at the anticipated scale, achieving over 90% coverage.
  - SMC was highly acceptable to stakeholders
  - SPAQ was found to be very well tolerated with no serious adverse reaction
  - RCT children in intervention districts had a 92.2% lower risk of developing confirmed malaria in the five-month period of follow-up versus those in the control
  - A reduction in malaria incidence in the intervention districts post SMC



## Best Practices - 2

- Modifications to the mass LLIN distribution campaign to improve efficiency
  - Established electronic Distribution management system for mass LLIN distribution
  - Last Mile distribution by National Medical Stores
  - PFMA / FAA
- Implementation of IRS through the Government structures
  - Improved Local ownership
  - Capacity building at sub national level

# Gap Analysis

# Summary

	2024	2025	2026	Total (2024-2026)
Total Need	141,406,046	134,756,982	264,340,958	540,503,986
Available	107,244,770	99,715,045	216,872,931	150,981,536
Gap	34,161,276	35,041,937	47,468,027	116,671,241

# Individual Commodities

<b>First line ACTs - Facility based case management - Uncomplicated Malaria</b>	<b>2024</b>	<b>2025</b>	<b>2026</b>	<b>Total (2024-2026)</b>
Total Need	6,710,509	6,199,845	6,581,215	19,491,568
GOU	1,143,427	1,143,427	1,143,427	3,430,281
PMI	671,051	619,984	658,121	1,949,157
GF Allocation	4,896,031	4,436,433	4,779,666	14,112,131
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>First line ACTs - ICCM - Uncomplicated</b>				
Total Need	1,095,282	1,042,596	1,139,280	3,277,158
PMI-MAPD	109,528	104,260	113,928	327,716
GF GC7 Allocation	985,753	938,337	1,025,352	2,949,442
<b>Gap</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Second Line ACTs</b>	<b>2024</b>	<b>2025</b>	<b>2026</b>	<b>Total (2024-2026)</b>
Total Need	2,398,839	2,295,266	2,464,419	7,158,524
GOU	-	-	-	-
PMI	-	-	-	-
GF Allocation	2,398,839	2,295,266	2,464,419	7,158,524
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

<b>ACTs - Private sector co-payment</b>	<b>2024</b>	<b>2025</b>	<b>2026</b>	<b>Total (2024-2026)</b>
Total Need	3,309,357	3,006,559	3,137,408	9,453,324
GOU (Domestic Sources)	-	-	-	-
PMI (External resources )	-	-	-	-
GF GC7 Allocation	3,309,357	787,653	-	4,097,010
<b>Gap</b>	<b>--</b>	<b>2,218,906</b>	<b>3,137,408</b>	<b>5,356,314</b>
<b>Malaria RDTs - Facility based case mgt</b>				
Total Need	9,186,687	9,645,589	10,187,987	29,020,263
GOU	-	-	-	-
PMI	918,669	964,559	1,018,799	2,902,026
GF GC7 Allocation	8,268,018	8,681,030	8,957,944	25,906,993
<b>Gap</b>	<b>-</b>	<b>--</b>	<b>211,244</b>	<b>211,244</b>
<b>Malaria RDTs - ICCM</b>				
Total Need	2,485,668	2,800,084	3,139,042	8,424,794
PMI (External resources )	248,567	280,008	313,904	842,479
GF GC7 Allocation	2,237,101	2,520,075	2,392,649	7,149,825
Gap			432,489	432,489

<b>Malaria RDTs - PRIVATE SECTOR COPAYMENT</b>	<b>2024</b>	<b>2025</b>	<b>2026</b>	<b>Total (2024-2026)</b>
Total Need	2,289,451	2,461,473	2,635,167	7,386,091
GOU (Domestic Sources)	-	-	-	-
PMI (External resources )	-	-	-	-
GF GC7 Allocation	2,289,451	918,949	-	3,208,400
<b>Gap</b>	<b>-</b>	<b>1,542,524</b>	<b>2,635,167</b>	<b>4,177,691</b>
<b>Artesunate injection allocation</b>				
Total Need	5,609,316	5,199,256	5,536,915	16,345,486
PMI (External resources )	560,932	519,926	553,691	1,634,549
GF GC7 Allocation	5,048,384	4,679,330	4,983,223	14,710,938
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Rectal Artesunate - Facility based case Mgt</b>				

<b>Rectal Artesunate - ICCM</b>	2024	2025	2026	Total (2024-2026)
Total Need	42,935	40,870	44,660	128,465
GOU	-	-	-	-
PMI	-	-	-	-
GF GC7	42,935	40,870	31,320	115,125
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>13,339</b>	<b>13,339</b>
<b>Examination Gloves - ICCM</b>				
Total Need	1,156,107	1,302,344	1,459,997	3,918,448
GOU	-	-	-	-
PMI	-	-	-	-
GF GC7	-	-	-	-
<b>Gap</b>	<b>- 1,156,107</b>	<b>- 1,302,344</b>	<b>- 1,459,997</b>	<b>- 3,918,448</b>
<b>Sharps Containers - ICCM</b>				
Total Need	189,565	189,565	189,565	568,695
GOU	-	-	-	-
PMI	-	-	-	-
GF GC7	189,565	132,695	132,695	454,956
<b>Gap</b>	<b>-</b>	<b>56,869</b>	<b>56,869</b>	<b>- 113,739</b>



<b>Non Malaria Commodities - ICCM</b>	<b>2,024</b>	<b>2,025</b>	<b>2,026</b>	<b>Total (2024-2026)</b>
Total Need	2,208,127	2,208,127	2,208,127	6,624,380
GOU	-	-	-	-
PMI	-	-	-	-
GF GC7	-	-	-	-
<b>Gap</b>	<b>2,208,127</b>	<b>2,208,127</b>	<b>2,208,127</b>	<b>6,624,380</b>
<b>LLINS - Mass Net Distribution</b>				
Total Need			126,867,877	126,867,877
PMI			4,000,000	4,000,000
AMF			24,501,374	24,501,374
GF GC7			82,737,586	82,737,586
<b>Gap</b>			<b>- 15,628,917</b>	<b>- 15,628,917</b>
<b>LLINS - Routine Net distribution</b>				

<b>Indoor Residual Spraying (IRS)</b>	<b>2,024</b>	<b>2,025</b>	<b>2,026</b>	<b>Total (2024-2026)</b>
Total Need	12,497,253	10,727,755	11,052,627	34,277,634
GOU	-	-	-	-
PMI	4,485,961	3,263,010	3,361,879	11,110,850
GF GC 7	8,011,291	7,464,745	7,269,218	22,745,254
<b>Gap</b>	-	-	<b>421,529</b>	<b>421,529</b>
<b>Seasonal Malaria Chemoprevention (SMC)</b>				
Total Need	523,767	530,366	535,912	1,590,045
GOU	-	-	-	-
PMI	-	-	-	-
GF GC 7	314,260	318,220	321,547	954,027
<b>Gap</b>	-	-	-	-
	<b>209,507</b>	<b>212,146</b>	<b>214,365</b>	<b>636,018</b>

Targeted Mass Drug Administration (MDA)	2024	2025	2026	Total (2024-2026)
Total Need	-	1,393,740	-	1,393,740
GOU	-	-	-	-
PMI	-	-	-	-
GF GC 7	-	-	-	-
<b>Gap</b>	<b>-</b>	<b>1,393,740</b>	<b>-</b>	<b>1,393,740</b>
<b>First Line ACTs – CCM</b>				
Total Need	396,598	414,938	513,929	1,325,464
GOU	-	-	-	-
PMI	-	-	-	-
GF GC 7	-	-	-	-
<b>Gap</b>	<b>- 396,598</b>	<b>- 414,938</b>	<b>- 513,929</b>	<b>- 1,325,464</b>
<b>Malaria RDTs – CCM</b>				
Total Need	456,881	510,490	574,472	1,541,842
GOU	-	-	-	-
PMI	-	-	-	-
GF GC 7	-	-	-	-
<b>Gap</b>	<b>- 456,881</b>	<b>- 510,490</b>	<b>- 574,472</b>	<b>- 1,541,842</b>

<b>Examination Gloves - CCM</b>	2024	2025	2026	Total funding (2024-2026)
Total Need	262,620	283,654	304,696	850,970
GOU	-	-	-	-
PMI	-	-	-	-
GF GC 7	-	-	-	-
<b>Gap</b>	<b>- 262,620 -</b>	<b>- 283,654 -</b>	<b>- 304,696 -</b>	<b>- 850,970</b>
<b>Safety Boxes - CCM</b>				
Total Need	49,417	49,417	49,417	148,251
GOU	-	-	-	-
PMI	-	-	-	-
GF GC 7	-	-	-	-
<b>Gap</b>	<b>- 49,417 -</b>	<b>- 49,417 -</b>	<b>- 49,417 -</b>	<b>- 148,251</b>
<b>Intermittent Preventive Therapy in Pregnancy (IPTp)</b>				
Total Need	1,209,551	1,303,572	1,357,660	3,870,784
GOU	-	-	-	-
PMI	1,209,551	1,303,572	1,357,660	1,399,908
GF GC 7				-
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>- 2,470,875</b>

# NEED FOR EPIDEMIC RESPONSE

<b>First line ACTs - Facility based case management</b>	<b>2024</b>	<b>2025</b>	<b>2026</b>	<b>Total (2024-2026)</b>
Total Need	570,393	929,977	987,182	2,487,552
GOU	-	-	-	-
PMI	57,039	92,998	98,718	248,755
GF GC 7	513,354	836,979	95,577	1,445,910
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>792,887</b>	<b>792,887</b>
<b>First line ACTs - ICCM - Uncomplicated</b>				
Total Need	16,429	52,130	113,928	182,487
PMI	1,643	5,213	11,393	18,249
GF GC 7	14,786	38,201	-	52,987
<b>Gap</b>	<b>-</b>	<b>8,716</b>	<b>102,535</b>	<b>111,251</b>
<b>Second Line ACTs - Facility based case management - Retreatment &amp; Post-discharge</b>				
Total Need	90,009	147,228	156,789	394,026
PMI	-	-	-	-
GF GC 7	90,009	147,228	-	237,237
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>156,789</b>	<b>156,789</b>

<b>Malaria RDTs - Facility based case mgt</b>	<b>2024</b>	<b>2025</b>	<b>2026Total (2024-2026)</b>	
Total Need	634,647	1,181,307	1,255,093	3,071,047
PMI	63,465	118,131	125,509	307,105
GF GC 7	-	-	-	-
<b>Gap</b>	<b>- 571,183</b>	<b>- 1,063,176</b>	<b>- 1,129,584</b>	<b>- 2,763,942</b>
<b>Malaria RDTs - ICCM</b>				
Total Need	37,285	140,004	313,904	491,193
PMI	3,729	14,000	31,390	49,119
GF GC 7	33,557	126,004	-	159,560
<b>Gap</b>	<b>-</b>	<b>-</b>	<b>- 282,514</b>	<b>- 282,514</b>
<b>Artesunate injection</b>				
Total Need	476,792	779,888	830,537	2,087,217
PMI	47,679	77,989	83,054	208,722
GF GC 7	429,113	541,472	-	970,585
<b>Gap</b>	<b>-</b>	<b>- 160,427</b>	<b>- 747,483</b>	<b>- 907,911</b>